Table of Content

1 Study Coverage
1.1 CD30 (TNFRSF8) Antibody Product Introduction
1.2 Market by Type
1.2.1 Global CD30 (TNFRSF8) Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global CD30 (TNFRSF8) Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Flow Cytometry
1.3.3 ELISA
1.3.4 Western Blot
1.3.5 Immunofluorescence
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts 2018-2029
2.2 Global CD30 (TNFRSF8) Antibody Revenue by Region
2.2.1 Global CD30 (TNFRSF8) Antibody Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global CD30 (TNFRSF8) Antibody Revenue by Region (2018-2024)
2.2.3 Global CD30 (TNFRSF8) Antibody Revenue by Region (2024-2029)
2.2.4 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2018-2029)
2.3 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts 2018-2029
2.4 Global CD30 (TNFRSF8) Antibody Sales by Region
2.4.1 Global CD30 (TNFRSF8) Antibody Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global CD30 (TNFRSF8) Antibody Sales by Region (2018-2024)
2.4.3 Global CD30 (TNFRSF8) Antibody Sales by Region (2024-2029)
2.4.4 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers
3.1.1 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2018-2024)
3.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of CD30 (TNFRSF8) Antibody in 2022
3.2 Global CD30 (TNFRSF8) Antibody Revenue by Manufacturers
3.2.1 Global CD30 (TNFRSF8) Antibody Revenue by Manufacturers (2018-2024)
3.2.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by CD30 (TNFRSF8) Antibody Revenue in 2022
3.3 Global Key Players of CD30 (TNFRSF8) Antibody, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global CD30 (TNFRSF8) Antibody Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Product Offered and Application
3.8 Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global CD30 (TNFRSF8) Antibody Sales by Type
4.1.1 Global CD30 (TNFRSF8) Antibody Historical Sales by Type (2018-2024)
4.1.2 Global CD30 (TNFRSF8) Antibody Forecasted Sales by Type (2024-2029)
4.1.3 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
4.2 Global CD30 (TNFRSF8) Antibody Revenue by Type
4.2.1 Global CD30 (TNFRSF8) Antibody Historical Revenue by Type (2018-2024)
4.2.2 Global CD30 (TNFRSF8) Antibody Forecasted Revenue by Type (2024-2029)
4.2.3 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
4.3 Global CD30 (TNFRSF8) Antibody Price by Type
4.3.1 Global CD30 (TNFRSF8) Antibody Price by Type (2018-2024)
4.3.2 Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global CD30 (TNFRSF8) Antibody Sales by Application
5.1.1 Global CD30 (TNFRSF8) Antibody Historical Sales by Application (2018-2024)
5.1.2 Global CD30 (TNFRSF8) Antibody Forecasted Sales by Application (2024-2029)
5.1.3 Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
5.2 Global CD30 (TNFRSF8) Antibody Revenue by Application
5.2.1 Global CD30 (TNFRSF8) Antibody Historical Revenue by Application (2018-2024)
5.2.2 Global CD30 (TNFRSF8) Antibody Forecasted Revenue by Application (2024-2029)
5.2.3 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
5.3 Global CD30 (TNFRSF8) Antibody Price by Application
5.3.1 Global CD30 (TNFRSF8) Antibody Price by Application (2018-2024)
5.3.2 Global CD30 (TNFRSF8) Antibody Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada CD30 (TNFRSF8) Antibody Market Size by Type
6.1.1 US & Canada CD30 (TNFRSF8) Antibody Sales by Type (2018-2029)
6.1.2 US & Canada CD30 (TNFRSF8) Antibody Revenue by Type (2018-2029)
6.2 US & Canada CD30 (TNFRSF8) Antibody Market Size by Application
6.2.1 US & Canada CD30 (TNFRSF8) Antibody Sales by Application (2018-2029)
6.2.2 US & Canada CD30 (TNFRSF8) Antibody Revenue by Application (2018-2029)
6.3 US & Canada CD30 (TNFRSF8) Antibody Market Size by Country
6.3.1 US & Canada CD30 (TNFRSF8) Antibody Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada CD30 (TNFRSF8) Antibody Sales by Country (2018-2029)
6.3.3 US & Canada CD30 (TNFRSF8) Antibody Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe CD30 (TNFRSF8) Antibody Market Size by Type
7.1.1 Europe CD30 (TNFRSF8) Antibody Sales by Type (2018-2029)
7.1.2 Europe CD30 (TNFRSF8) Antibody Revenue by Type (2018-2029)
7.2 Europe CD30 (TNFRSF8) Antibody Market Size by Application
7.2.1 Europe CD30 (TNFRSF8) Antibody Sales by Application (2018-2029)
7.2.2 Europe CD30 (TNFRSF8) Antibody Revenue by Application (2018-2029)
7.3 Europe CD30 (TNFRSF8) Antibody Market Size by Country
7.3.1 Europe CD30 (TNFRSF8) Antibody Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe CD30 (TNFRSF8) Antibody Sales by Country (2018-2029)
7.3.3 Europe CD30 (TNFRSF8) Antibody Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China CD30 (TNFRSF8) Antibody Market Size
8.1.1 China CD30 (TNFRSF8) Antibody Sales (2018-2029)
8.1.2 China CD30 (TNFRSF8) Antibody Revenue (2018-2029)
8.2 China CD30 (TNFRSF8) Antibody Market Size by Application
8.2.1 China CD30 (TNFRSF8) Antibody Sales by Application (2018-2029)
8.2.2 China CD30 (TNFRSF8) Antibody Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia CD30 (TNFRSF8) Antibody Market Size by Type
9.1.1 Asia CD30 (TNFRSF8) Antibody Sales by Type (2018-2029)
9.1.2 Asia CD30 (TNFRSF8) Antibody Revenue by Type (2018-2029)
9.2 Asia CD30 (TNFRSF8) Antibody Market Size by Application
9.2.1 Asia CD30 (TNFRSF8) Antibody Sales by Application (2018-2029)
9.2.2 Asia CD30 (TNFRSF8) Antibody Revenue by Application (2018-2029)
9.3 Asia CD30 (TNFRSF8) Antibody Sales by Region
9.3.1 Asia CD30 (TNFRSF8) Antibody Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia CD30 (TNFRSF8) Antibody Revenue by Region (2018-2029)
9.3.3 Asia CD30 (TNFRSF8) Antibody Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Market Size by Type
10.1.1 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Market Size by Application
10.2.1 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Country
10.3.1 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Sino Biological, Inc.
11.1.1 Sino Biological, Inc. Company Information
11.1.2 Sino Biological, Inc. Overview
11.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sino Biological, Inc. Recent Developments
11.2 Bio-Techne
11.2.1 Bio-Techne Company Information
11.2.2 Bio-Techne Overview
11.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Bio-Techne CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bio-Techne Recent Developments
11.3 Thermo Fisher Scientific (China) Co., Ltd.
11.3.1 Thermo Fisher Scientific (China) Co., Ltd. Company Information
11.3.2 Thermo Fisher Scientific (China) Co., Ltd. Overview
11.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
11.4 Boster Biological Technology
11.4.1 Boster Biological Technology Company Information
11.4.2 Boster Biological Technology Overview
11.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Boster Biological Technology Recent Developments
11.5 MyBiosource, Inc.
11.5.1 MyBiosource, Inc. Company Information
11.5.2 MyBiosource, Inc. Overview
11.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 MyBiosource, Inc. Recent Developments
11.6 Abeomics Inc.
11.6.1 Abeomics Inc. Company Information
11.6.2 Abeomics Inc. Overview
11.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Abeomics Inc. Recent Developments
11.7 Abbexa
11.7.1 Abbexa Company Information
11.7.2 Abbexa Overview
11.7.3 Abbexa CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Abbexa CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Abbexa Recent Developments
11.8 Cell Signaling Technology, Inc.
11.8.1 Cell Signaling Technology, Inc. Company Information
11.8.2 Cell Signaling Technology, Inc. Overview
11.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Cell Signaling Technology, Inc. Recent Developments
11.9 Creative Diagnostics
11.9.1 Creative Diagnostics Company Information
11.9.2 Creative Diagnostics Overview
11.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Creative Diagnostics Recent Developments
11.10 OriGene Technologies, Inc.
11.10.1 OriGene Technologies, Inc. Company Information
11.10.2 OriGene Technologies, Inc. Overview
11.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 OriGene Technologies, Inc. Recent Developments
11.11 Merck
11.11.1 Merck Company Information
11.11.2 Merck Overview
11.11.3 Merck CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Merck CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Merck Recent Developments
11.12 Cayman Chemical
11.12.1 Cayman Chemical Company Information
11.12.2 Cayman Chemical Overview
11.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Cayman Chemical CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Cayman Chemical Recent Developments
11.13 CUSABIO
11.13.1 CUSABIO Company Information
11.13.2 CUSABIO Overview
11.13.3 CUSABIO CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 CUSABIO CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 CUSABIO Recent Developments
11.14 Biotium
11.14.1 Biotium Company Information
11.14.2 Biotium Overview
11.14.3 Biotium CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Biotium CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Biotium Recent Developments
11.15 BioLegend
11.15.1 BioLegend Company Information
11.15.2 BioLegend Overview
11.15.3 BioLegend CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 BioLegend CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 BioLegend Recent Developments
11.16 Abcepta
11.16.1 Abcepta Company Information
11.16.2 Abcepta Overview
11.16.3 Abcepta CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Abcepta CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Abcepta Recent Developments
11.17 ProSci Incorporated
11.17.1 ProSci Incorporated Company Information
11.17.2 ProSci Incorporated Overview
11.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 ProSci Incorporated Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
12.2 CD30 (TNFRSF8) Antibody Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 CD30 (TNFRSF8) Antibody Production Mode & Process
12.4 CD30 (TNFRSF8) Antibody Sales and Marketing
12.4.1 CD30 (TNFRSF8) Antibody Sales Channels
12.4.2 CD30 (TNFRSF8) Antibody Distributors
12.5 CD30 (TNFRSF8) Antibody Customers
13 Market Dynamics
13.1 CD30 (TNFRSF8) Antibody Industry Trends
13.2 CD30 (TNFRSF8) Antibody Market Drivers
13.3 CD30 (TNFRSF8) Antibody Market Challenges
13.4 CD30 (TNFRSF8) Antibody Market Restraints
14 Key Findings in The Global CD30 (TNFRSF8) Antibody Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global CD30 (TNFRSF8) Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Monoclonal Antibody
Table 3. Major Manufacturers of Polyclonal Antibody
Table 4. Global CD30 (TNFRSF8) Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global CD30 (TNFRSF8) Antibody Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global CD30 (TNFRSF8) Antibody Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global CD30 (TNFRSF8) Antibody Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2018-2024)
Table 9. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2024-2029)
Table 10. Global CD30 (TNFRSF8) Antibody Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global CD30 (TNFRSF8) Antibody Sales by Region (2018-2024) & (K Units)
Table 12. Global CD30 (TNFRSF8) Antibody Sales by Region (2024-2029) & (K Units)
Table 13. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2018-2024)
Table 14. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2024-2029)
Table 15. Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global CD30 (TNFRSF8) Antibody Sales Share by Manufacturers (2018-2024)
Table 17. Global CD30 (TNFRSF8) Antibody Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of CD30 (TNFRSF8) Antibody, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. CD30 (TNFRSF8) Antibody Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global CD30 (TNFRSF8) Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2022)
Table 23. Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Product Offered and Application
Table 25. Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global CD30 (TNFRSF8) Antibody Sales by Type (2018-2024) & (K Units)
Table 28. Global CD30 (TNFRSF8) Antibody Sales by Type (2024-2029) & (K Units)
Table 29. Global CD30 (TNFRSF8) Antibody Sales Share by Type (2018-2024)
Table 30. Global CD30 (TNFRSF8) Antibody Sales Share by Type (2024-2029)
Table 31. Global CD30 (TNFRSF8) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global CD30 (TNFRSF8) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global CD30 (TNFRSF8) Antibody Revenue Share by Type (2018-2024)
Table 34. Global CD30 (TNFRSF8) Antibody Revenue Share by Type (2024-2029)
Table 35. CD30 (TNFRSF8) Antibody Price by Type (2018-2024) & (US$/Unit)
Table 36. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global CD30 (TNFRSF8) Antibody Sales by Application (2018-2024) & (K Units)
Table 38. Global CD30 (TNFRSF8) Antibody Sales by Application (2024-2029) & (K Units)
Table 39. Global CD30 (TNFRSF8) Antibody Sales Share by Application (2018-2024)
Table 40. Global CD30 (TNFRSF8) Antibody Sales Share by Application (2024-2029)
Table 41. Global CD30 (TNFRSF8) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global CD30 (TNFRSF8) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global CD30 (TNFRSF8) Antibody Revenue Share by Application (2018-2024)
Table 44. Global CD30 (TNFRSF8) Antibody Revenue Share by Application (2024-2029)
Table 45. CD30 (TNFRSF8) Antibody Price by Application (2018-2024) & (US$/Unit)
Table 46. Global CD30 (TNFRSF8) Antibody Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada CD30 (TNFRSF8) Antibody Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada CD30 (TNFRSF8) Antibody Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada CD30 (TNFRSF8) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada CD30 (TNFRSF8) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada CD30 (TNFRSF8) Antibody Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada CD30 (TNFRSF8) Antibody Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada CD30 (TNFRSF8) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada CD30 (TNFRSF8) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada CD30 (TNFRSF8) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada CD30 (TNFRSF8) Antibody Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada CD30 (TNFRSF8) Antibody Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada CD30 (TNFRSF8) Antibody Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada CD30 (TNFRSF8) Antibody Sales by Country (2024-2029) & (K Units)
Table 60. Europe CD30 (TNFRSF8) Antibody Sales by Type (2018-2024) & (K Units)
Table 61. Europe CD30 (TNFRSF8) Antibody Sales by Type (2024-2029) & (K Units)
Table 62. Europe CD30 (TNFRSF8) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe CD30 (TNFRSF8) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe CD30 (TNFRSF8) Antibody Sales by Application (2018-2024) & (K Units)
Table 65. Europe CD30 (TNFRSF8) Antibody Sales by Application (2024-2029) & (K Units)
Table 66. Europe CD30 (TNFRSF8) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe CD30 (TNFRSF8) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe CD30 (TNFRSF8) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe CD30 (TNFRSF8) Antibody Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe CD30 (TNFRSF8) Antibody Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe CD30 (TNFRSF8) Antibody Sales by Country (2018-2024) & (K Units)
Table 72. Europe CD30 (TNFRSF8) Antibody Sales by Country (2024-2029) & (K Units)
Table 73. China CD30 (TNFRSF8) Antibody Sales by Type (2018-2024) & (K Units)
Table 74. China CD30 (TNFRSF8) Antibody Sales by Type (2024-2029) & (K Units)
Table 75. China CD30 (TNFRSF8) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 76. China CD30 (TNFRSF8) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 77. China CD30 (TNFRSF8) Antibody Sales by Application (2018-2024) & (K Units)
Table 78. China CD30 (TNFRSF8) Antibody Sales by Application (2024-2029) & (K Units)
Table 79. China CD30 (TNFRSF8) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 80. China CD30 (TNFRSF8) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia CD30 (TNFRSF8) Antibody Sales by Type (2018-2024) & (K Units)
Table 82. Asia CD30 (TNFRSF8) Antibody Sales by Type (2024-2029) & (K Units)
Table 83. Asia CD30 (TNFRSF8) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia CD30 (TNFRSF8) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia CD30 (TNFRSF8) Antibody Sales by Application (2018-2024) & (K Units)
Table 86. Asia CD30 (TNFRSF8) Antibody Sales by Application (2024-2029) & (K Units)
Table 87. Asia CD30 (TNFRSF8) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia CD30 (TNFRSF8) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia CD30 (TNFRSF8) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia CD30 (TNFRSF8) Antibody Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia CD30 (TNFRSF8) Antibody Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia CD30 (TNFRSF8) Antibody Sales by Region (2018-2024) & (K Units)
Table 93. Asia CD30 (TNFRSF8) Antibody Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales by Country (2024-2029) & (K Units)
Table 107. Sino Biological, Inc. Company Information
Table 108. Sino Biological, Inc. Description and Major Businesses
Table 109. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Sino Biological, Inc. Recent Developments
Table 112. Bio-Techne Company Information
Table 113. Bio-Techne Description and Major Businesses
Table 114. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Bio-Techne CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Bio-Techne Recent Developments
Table 117. Thermo Fisher Scientific (China) Co., Ltd. Company Information
Table 118. Thermo Fisher Scientific (China) Co., Ltd. Description and Major Businesses
Table 119. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
Table 122. Boster Biological Technology Company Information
Table 123. Boster Biological Technology Description and Major Businesses
Table 124. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Boster Biological Technology Recent Developments
Table 127. MyBiosource, Inc. Company Information
Table 128. MyBiosource, Inc. Description and Major Businesses
Table 129. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. MyBiosource, Inc. Recent Developments
Table 132. Abeomics Inc. Company Information
Table 133. Abeomics Inc. Description and Major Businesses
Table 134. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Abeomics Inc. Recent Developments
Table 137. Abbexa Company Information
Table 138. Abbexa Description and Major Businesses
Table 139. Abbexa CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Abbexa CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Abbexa Recent Developments
Table 142. Cell Signaling Technology, Inc. Company Information
Table 143. Cell Signaling Technology, Inc. Description and Major Businesses
Table 144. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Cell Signaling Technology, Inc. Recent Developments
Table 147. Creative Diagnostics Company Information
Table 148. Creative Diagnostics Description and Major Businesses
Table 149. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Creative Diagnostics Recent Developments
Table 152. OriGene Technologies, Inc. Company Information
Table 153. OriGene Technologies, Inc. Description and Major Businesses
Table 154. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. OriGene Technologies, Inc. Recent Developments
Table 157. Merck Company Information
Table 158. Merck Description and Major Businesses
Table 159. Merck CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Merck CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Merck Recent Developments
Table 162. Cayman Chemical Company Information
Table 163. Cayman Chemical Description and Major Businesses
Table 164. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Cayman Chemical CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Cayman Chemical Recent Developments
Table 167. CUSABIO Company Information
Table 168. CUSABIO Description and Major Businesses
Table 169. CUSABIO CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. CUSABIO CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. CUSABIO Recent Developments
Table 172. Biotium Company Information
Table 173. Biotium Description and Major Businesses
Table 174. Biotium CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Biotium CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Biotium Recent Developments
Table 177. BioLegend Company Information
Table 178. BioLegend Description and Major Businesses
Table 179. BioLegend CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 180. BioLegend CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. BioLegend Recent Developments
Table 182. Abcepta Company Information
Table 183. Abcepta Description and Major Businesses
Table 184. Abcepta CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 185. Abcepta CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Abcepta Recent Developments
Table 187. ProSci Incorporated Company Information
Table 188. ProSci Incorporated Description and Major Businesses
Table 189. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 190. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. ProSci Incorporated Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. CD30 (TNFRSF8) Antibody Distributors List
Table 195. CD30 (TNFRSF8) Antibody Customers List
Table 196. CD30 (TNFRSF8) Antibody Market Trends
Table 197. CD30 (TNFRSF8) Antibody Market Drivers
Table 198. CD30 (TNFRSF8) Antibody Market Challenges
Table 199. CD30 (TNFRSF8) Antibody Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. CD30 (TNFRSF8) Antibody Product Picture
Figure 2. Global CD30 (TNFRSF8) Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global CD30 (TNFRSF8) Antibody Market Share by Type in 2022 & 2029
Figure 4. Monoclonal Antibody Product Picture
Figure 5. Polyclonal Antibody Product Picture
Figure 6. Global CD30 (TNFRSF8) Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2022 & 2029
Figure 8. Flow Cytometry
Figure 9. ELISA
Figure 10. Western Blot
Figure 11. Immunofluorescence
Figure 12. Others
Figure 13. CD30 (TNFRSF8) Antibody Report Years Considered
Figure 14. Global CD30 (TNFRSF8) Antibody Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global CD30 (TNFRSF8) Antibody Revenue 2018-2029 (US$ Million)
Figure 16. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2018-2029)
Figure 18. Global CD30 (TNFRSF8) Antibody Sales 2018-2029 ((K Units)
Figure 19. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2018-2029)
Figure 20. US & Canada CD30 (TNFRSF8) Antibody Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada CD30 (TNFRSF8) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe CD30 (TNFRSF8) Antibody Sales YoY (2018-2029) & (K Units)
Figure 23. Europe CD30 (TNFRSF8) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China CD30 (TNFRSF8) Antibody Sales YoY (2018-2029) & (K Units)
Figure 25. China CD30 (TNFRSF8) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) CD30 (TNFRSF8) Antibody Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) CD30 (TNFRSF8) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The CD30 (TNFRSF8) Antibody Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of CD30 (TNFRSF8) Antibody in the World: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2022
Figure 32. Global CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
Figure 34. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
Figure 35. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
Figure 36. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
Figure 38. US & Canada CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
Figure 40. US & Canada CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada CD30 (TNFRSF8) Antibody Revenue Share by Country (2018-2029)
Figure 42. US & Canada CD30 (TNFRSF8) Antibody Sales Share by Country (2018-2029)
Figure 43. U.S. CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 44. Canada CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 45. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
Figure 46. Europe CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
Figure 47. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
Figure 48. Europe CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
Figure 49. Europe CD30 (TNFRSF8) Antibody Revenue Share by Country (2018-2029)
Figure 50. Europe CD30 (TNFRSF8) Antibody Sales Share by Country (2018-2029)
Figure 51. Germany CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 52. France CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 54. Italy CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 55. Russia CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 56. China CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
Figure 57. China CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
Figure 58. China CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
Figure 59. China CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
Figure 60. Asia CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
Figure 61. Asia CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
Figure 62. Asia CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
Figure 63. Asia CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
Figure 64. Asia CD30 (TNFRSF8) Antibody Revenue Share by Region (2018-2029)
Figure 65. Asia CD30 (TNFRSF8) Antibody Sales Share by Region (2018-2029)
Figure 66. Japan CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 70. India CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America CD30 (TNFRSF8) Antibody Sales Share by Country (2018-2029)
Figure 77. Brazil CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 80. Israel CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries CD30 (TNFRSF8) Antibody Revenue (2018-2029) & (US$ Million)
Figure 82. CD30 (TNFRSF8) Antibody Value Chain
Figure 83. CD30 (TNFRSF8) Antibody Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed